0 of 4 questions completed
You have already completed the quiz before. Hence you can not start it again.
Quiz is loading…
You must sign in or sign up to start the quiz.
You must first complete the following:
0 of 4 questions answered correctly
Time has elapsed
You have reached 0 of 0 point(s), (0)
Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)
You must score 80% to continue. Please click the link below to re-take the quiz
1. According to 2017 European Leukemia Net (ELN) guidelines, which of the following genetic-cytogentic profiles is assigned to the intermediate prognostic subgroup?
2. All of the following statements regarding minimal residual disease (MRD) are accurate, except
3. You are developing the treatment plan for a 52 -year-old man with newly-diagnosed AML. Because the patient is stable and does not require immediate therapy, you decide to wait for results of cytogenetics testing. Those results indicate that the patient is in the ELN intermediate risk group. Blasts show CD33 expression. You would like to offer the patient stem cell transplant at first remission. In considering using gemtuzumab ozogamicin (GO) in combination with daunorubicin and cytarabine for induction therapy, which of the following is most important to consider?
4. In the RATIFY trial, that compared midostaurin to placebo in patients with newly diagnosed AML with FLT3 mutation, overall survival at 4 years in the midostaurin-treated group was ____ % compared to 44% in the placebo-treated group.